Sign in
Not yet recruitingPhase 3

The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.

Key facts

Who runs it
GL Pharm Tech Corporation
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
228 people, planned
Started
Sept 2026
Expected to end
Jul 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • W2505
  • W2505-P1
  • W2505-R
  • W2505-P2
Record updated
5 October 2026

Who can take part

Age
19 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Male aged 19 years or older
  • Capable of completing study diaries and questionnaires independently
  • Signed written informed consent
  • run-in medication compliance ≥ 70%

Who cannot take part

  • Erectile dysfunction caused by premature ejaculation or untreated endocrine disorders (e.g., untreated hypogonadism, hyperprolactinemia)
  • Primary hypoactive sexual desire
  • Other exclusions applied

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of W2505.

The 3 groups in the trial

  • ExperimentalTreatment being tested

    W2505 and W2505-P2, 12 weeks.

    Treatment: W2505 and W2505-P2

  • Placebo ComparatorPlacebo, for comparison

    W2505-P1 and W2505-P2, 12 weeks.

    Treatment: W2505-P1 and W2505-P2

  • Active ComparatorExisting treatment, for comparison

    W2505-P1 and W2505-R, 12 weeks.

    Treatment: W2505-P1 and W2505-R

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of W2505
Record updated
5 October 2026